Pfizer posts late-stage trial win for multiple myeloma drug Elrexfio in an earlier line setting
JHVEPhoto/iStock Editorial via Getty Images
Pfizer (PFE) on Tuesday announced a successful late-stage trial outcome for its multiple myeloma therapy, Elrexfio (elranatamab), when used in an earlier-line setting against the hematological cancer.
Based on topline data, the New York-based drugmaker said it succeeded in its Phase
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.